Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results

Eyepoint Pharmaceuticals (NASDAQ:EYPT) released its quarterly earnings results on Wednesday. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09), Zacks reports. The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.39 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.

Eyepoint Pharmaceuticals Trading Up 4.7%

Shares of NASDAQ:EYPT traded up $0.58 during trading on Thursday, hitting $12.83. 2,237,980 shares of the company were exchanged, compared to its average volume of 1,280,019. Eyepoint Pharmaceuticals has a fifty-two week low of $9.65 and a fifty-two week high of $19.11. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.67 and a beta of 1.76. The firm has a fifty day moving average price of $13.12 and a two-hundred day moving average price of $13.79.

Analysts Set New Price Targets

A number of analysts have recently issued reports on EYPT shares. Royal Bank Of Canada lowered their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald raised their target price on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Stifel Nicolaus initiated coverage on shares of Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Chardan Capital boosted their price target on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $44.38.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in shares of Eyepoint Pharmaceuticals in the 4th quarter valued at about $53,658,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth about $28,556,000. Orbimed Advisors LLC bought a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at about $25,575,000. Suvretta Capital Management LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after purchasing an additional 1,634,970 shares during the period. Finally, Federated Hermes Inc. lifted its stake in Eyepoint Pharmaceuticals by 36.3% in the 4th quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after purchasing an additional 1,601,101 shares during the last quarter. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.